Overview

A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer

Status:
Completed

Trial end date:
2017-12-15

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether PROSTVAC alone or in combination with GM-CSF is effective in prolonging overall survival in men with few or no symptoms from metastatic, castrate-resistant prostate cancer.

Phase:

Phase 3

Details

Lead Sponsor:

Bavarian Nordic
Bavarian Nordic, Inc.

Treatments:

Molgramostim
Sargramostim